AACR 2022: Follow up of a study examining zanubrutinib compared with ibrutinib for treatment of relapsed chronic lymphocytic leukemia.
Home / Resource Library / Final Response Analysis of ALPINE Trial Shows Superior ORR With Zanubrutinib Vs Ibrutinib in CLL